The PD-L1 targeted Dox liposomal formulation here developed and assayed in a melanoma murine model, has demonstrated an enhanced contribution of both components, α-PD-L1 and Dox, in the control of tumor growth and elimination, enabling host antitumor immune modulation. This evidence concerns the gene CD274 and melanoma.